HomeCompareCALT vs KMB

CALT vs KMB: Dividend Comparison 2026

CALT yields 5.00% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $18.1K in total portfolio value
10 years
CALT
CALT
● Live price
5.00%
Share price
$40.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$688.45
Full CALT calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — CALT vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCALTKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CALT + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CALT pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CALT
Annual income on $10K today (after 15% tax)
$425.00/yr
After 10yr DRIP, annual income (after tax)
$585.18/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KMB beats the other by $3,853.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CALT + KMB for your $10,000?

CALT: 50%KMB: 50%
100% KMB50/50100% CALT
Portfolio after 10yr
$36.8K
Annual income
$2,955.40/yr
Blended yield
8.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

CALT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$39.50
-1.3% upside vs current
Range: $39.00 — $40.00
Altman Z
8.0
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CALT buys
0
KMB buys
0
No recent congressional trades found for CALT or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCALTKMB
Forward yield5.00%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$27.8K$45.9K
Annual income after 10y$688.45$5,222.34
Total dividends collected$6.0K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$39.50$123.00

Year-by-year: CALT vs KMB ($10,000, DRIP)

YearCALT PortfolioCALT Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,200$500.00$11,314$614.45$114.00KMB
2$12,507$523.36$12,867$760.19$360.00KMB
3$13,929$546.22$14,713$945.27$784.00KMB
4$15,473$568.51$16,924$1,181.90$1.5KKMB
5$17,146$590.20$19,596$1,486.64$2.5KKMB
6$18,957$611.24$22,850$1,882.16$3.9KKMB
7$20,916$631.60$26,849$2,399.80$5.9KKMB
8$23,031$651.27$31,812$3,083.36$8.8KKMB
9$25,314$670.22$38,033$3,994.72$12.7KKMB
10$27,774$688.45$45,918$5,222.34$18.1KKMB

CALT vs KMB: Complete Analysis 2026

CALTStock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Full CALT Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this CALT vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CALT vs SCHDCALT vs JEPICALT vs OCALT vs KOCALT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.